课题基金 / 基金详情

PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL

PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
卡铂联合每周紫杉醇的 I 期药代动力学研究
批准号：
6304699
负责人：
CHANDRA BELANI
金额：
$0.3万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6304699
关键词：
carboplatin clinical research clinical trial phase I combination chemotherapy drug administration rate /duration drug adverse effect drug interactions drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy paclitaxel pharmacokinetics

项目摘要

项目成果

CHANDRA BELANI的其他基金

相似基金

相关文献

中文摘要
翻译
该研究的第一阶段要求每三周给卡铂与每周一次的紫杉醇联合使用。每周给药可显著提高紫杉醇的剂量强度，且血液毒性最小，此外，紫杉醇对卡铂所致的血小板减少也有保护作用。这是反对的是，紫杉醇在这种组合中剂量强度的增加将导致开发一种有效的方案，而不会增加毒性，每三周定期进行一次。
英文摘要
Phase I of the study calls for a combination of carboplatin given every three weeks with weekly paclitaxel. The dose intensity of paclitaxel can be increased considerably by weekly administration with minimal hematological toxicity and in addition, paclitaxel may also have a protective effect on carboplatin induced thrombocytopenia. It is anticpated that the increased dose intensity of paclitaxel in this combination would result in developing an active regimen without added toxicity as seen on a regular every three-week schedule.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE I STUDY IN ADVANCED SOLID MALIGNANCIES (NCI 7967)
CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI
Phase I Clinical Trials of Novel Anticancer Agents
海外基金